Soliris® and PNH
Soliris® (eculizumab) is the first and only therapy
specifically tested and approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH), an ultra-rare,
life-threatening blood disorder. Soliris has been approved for the treatment of patients with PNH in more than 40 countries worldwide.
PNH is a debilitating, ultra-rare and life-threatening blood disorder defined by chronic, uncontrolled complement activation which causes the chronic destruction of red blood cells (hemolysis), leading to blood clots, organ failure and shortened survival.2,3,6,7
Historically, up to 35% of patients with PNH treated with best supportive care have died within five years of diagnosis due to serious clinical outcomes such as thromboembolism (TE) and chronic kidney disease (CKD).3
Treating PNH with Soliris
Extensive clinical trials show that Soliris significantly reduces hemolysis in patients with PNH, leading to an improvement in
symptoms and a reduction in major health problems associated with the disease.9,10 For information on recently Published studies see References.
To learn more about PNH, visit www.PNHSource.com. To learn more about treatment with Soliris, visit www.Soliris.net.